Theophylline and cardiac stress in patients with dyspnea: An observational study

Pharmacology

Volumn 86, Issue 4, 2010, Pages 189-195

  Wieshammer, Siegfried ^a   Dreyhaupt, Jens ^b   Basler, Beate ^a  

^a Klinikum Offenburg   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Asthma; Cardiac stress; Cardiopulmonary interaction; Chronic obstructive pulmonary disease; Heart disease; Lung disease; Natriuretic peptides; Theophylline

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; THEOPHYLLINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPNEA; FEMALE; HEART STRESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIPLE REGRESSION; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; AIRWAY OBSTRUCTION; BRONCHODILATOR AGENTS; DYSPNEA; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREVALENCE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; THEOPHYLLINE;

EID: 77956106600     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318853     Document Type: Article

References (31)

1. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ: Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001; 164: 273-276. (Pubitemid 34001294)
2. Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, Ueshima K, Akamatsu K, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M: Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax 2006; 61: 761-766. (Pubitemid 44369399)
3. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A: Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009; 64: 424-429.
4. Shannon M: Life-threatening events after theophylline overdose. Arch Intern Med 1999; 159: 989-994.
5. Cazzola M, Donner CF, Gabriella Matera M: Long acting β 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54: 730-736. (Pubitemid 29341411)
6. Rutten FH, Cramer MJM, Grobbee DE, Sachs APE, Kirkels JH, Lammers JWJ, Hoes AW: Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894. (Pubitemid 41253302)
7. Curkendall SM, De Luise C, Jones JK, Lanes S, Stang MR, Goehring E, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70. (Pubitemid 41783891)
8. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos C: Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305: 249-252. (Pubitemid 12234750)
9. Jagers JV, Hawes HG, Easton PA: Aminophylline increases ventilation and diaphragm contractility in awake canines. Respir Physiol Neurobiol 2009; 167: 273-280.
10. Moxham J: Aminophylline and the respiratory muscles: an alternative view. Clin Chest Med 1988; 9: 325-336.
11. Andreas S, Reiter H, Lüthje L, Delekat A, Grunewald RW, Hasenfuss G, Somers VK: Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure. Circulation 2004; 110: 2157-2162. (Pubitemid 39372494)
12. Al-Damluji S, Nathan AW, Johnston A, Banim SO, Spurrell RA, Camm AJ: Oral theophylline in chronic heart failure. Postgrad Med J 1982; 58: 216-221. (Pubitemid 12100325)
13. Matthay RA: Favorable cardiovascular effects of theophylline in COPD. Chest 1987; 92(SUPPL.1):22S-26S.
14. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663. (Pubitemid 38364624)
15. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JGF, Cohen-Solal A, Dahlstrom U, De Maria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E: State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839.
16. Williams SG, Ng LL, O'Brian RJ, Taylor S, Wright DJ, Tan LB: Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study. Eur J Heart Fail 2004; 6: 891-900. (Pubitemid 39536305)
17. Wieshammer S, Dreyhaupt J, Basler B, Marsovszky E: NT-proBNP for pulmonologists: not only a rule-out test for systolic heart failure but also a global marker of heart disease. Respiration 2009; 77: 370-380.
18. Global Initiative for Asthma (GINA): National Institutes of Health, NHLBI/WHO workshop report (updated 2005). Bethesda, National Heart, Lung and Blood Institute, National Institutes of Health. www.ginasthma. com.
19. Celli BR, MacNee W, et al: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
20. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968. (Pubitemid 41632054)
21. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772. (Pubitemid 46580250)
22. Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167; 2003; 813-818. (Pubitemid 36801766)
23. Cazzola M, Gabriella Matera M: The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101: 957-962. (Pubitemid 46505992)
24. Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP: The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007; 137: 4-12. (Pubitemid 46191225)
25. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PWF, Sutherland P, Omland T, Vasan RS: Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254-258. (Pubitemid 34804560)
26. Park SJ, Cho KI, Jung SJ, Choi SW, Choi JW, Lee DW, Lee HG, Kim TI: N-terminal pro-Btype natriuretic peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. Korean Circ J 2009; 39: 538-544.
27. Lee-Chiong TL Jr, Matthay RA: Pulmonary hypertension and cor pulmonale in COPD. Semin Respir Crit Care Med 2003; 24: 263-272. (Pubitemid 36828967)
28. Wieshammer S, Dreyhaupt J, Basler B: A link between impaired lung function and increased cardiac stress. Respiration 2010; 79: 355-362.
29. Lee TA, Schumock GT, Bartle B, Pickard AS: Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease. Pharmacotherapy 2009; 29: 1039-1053.
30. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, the M2- 124 and M2-125 study groups: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
31. Currie GP, Butler CA, Anderson WJ, Skinner C: Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment. Br J Clin Pharmacol 2008; 65: 803-810. (Pubitemid 351677441)